BridgeBio Pharma IncBBIO
Price$66.91

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $713.1M+221.3% YoYTTM through 30 Jun 2026
Net Income -$702MTTM through 30 Jun 2026
Free Cash Flow -$435.4MTTM through 30 Jun 2026

Margins

Current
Gross Margin95.8%
EBITDA Margin-69.1%
Operating Margin-104.2%
Net Margin-98.5%

Returns

27.9%ROE
-78.3%ROA

Balance Sheet Health

Debt / Equity-1.30x
Current Ratio2.77x
Net Debt$1.3B
Cash & Equivalents$677.9M

Quality Metrics

Altman Z-Score-3.14
Piotroski F-Score2 / 9
FCF Margin-61.1%
Rule of 40-18.8
Earnings-Beat Rate25.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $502.1M
Diluted EPS-$3.56TTM
'20'21'22'23'24'25
FY2025: $-3.78

Dividend

No dividend

Capital Allocation

R&D Spend$505.4M
Capex Intensity0.1%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.